Form 4: Gyre Therapeutics President Sells Shares Under 10b5-1 Trading Plan

Gyre Therapeutics President, Songjiang Ma, sold a total of 2,216 shares of common stock on January 6th and 7th, 2025, under a pre-arranged 10b5-1 trading plan.

Summary

• Songjiang Ma, President of Gyre Therapeutics, sold 941 shares of common stock on January 6, 2025, at a weighted average price of $10.16 per share.
• On January 7, 2025, Mr. Ma sold an additional 1,275 shares of common stock at a weighted average price of $10.02 per share.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on September 13, 2024.
• The sales were made in multiple transactions with prices ranging from $10.00 to $10.76 on January 6th and $10.00 to $10.24 on January 7th.
• Following these transactions, Mr. Ma's spouse indirectly holds 2,916,251 shares of Gyre Therapeutics common stock.

Sentiment

Score: 5

Explanation: The document is a routine filing of insider stock sales under a pre-arranged plan, which is neither positive nor negative for the company's outlook.

Industry Context

Form 4 filings are standard practice for reporting insider transactions and are common across all publicly traded companies. The use of a 10b5-1 trading plan is a common method for insiders to sell shares while avoiding accusations of trading on non-public information.

Comparison to Industry Standards

• The reported transactions are consistent with standard practices for insider trading disclosures.
• Many executives at publicly traded companies use 10b5-1 plans to manage their personal finances and avoid potential conflicts of interest.
• The price ranges of the sales are within a normal range for market fluctuations.

Stakeholder Impact

• The stock sales by the President may have a minor impact on shareholder sentiment, but the use of a 10b5-1 plan mitigates concerns about insider trading.

Key Dates

Keywords

Form 4, insider trading, stock sale, Rule 10b5-1, Gyre Therapeutics, Songjiang Ma